Globus Medical Inc Stock Prediction and Forecast [GMED]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 08 Nov 2025, 04:37 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Globus Medical Inc Stock Prediction and Forecast [GMED]](https://i.ytimg.com/vi/c9Ihn7siQBw/hqdefault.jpg)
AI-generated source summary
This analysis of Globus Medical (GMED) stock, recorded on November 7th, 2025, presents a Hold recommendation with a score of 0.0, noting an average daily gain of 2.54% over the past 17 days. The stock broke an upward trend but potential support is found at $65.35. The three-month trend suggests a potential 4.28% increase, yet a 12-month analysis indicates a -29.76% change, with a price range between $28.63 and $58.93. Friday saw a gain of 35.94% closing at $83.89, however there is over valuation for the trading on Monday 10th.Recent insider trading showed a significant buying volume compared to selling volume Insider trading power is at 33.45. The analysis advises a stop-loss at $81.16, while a 14-day RSI stands at 87. A buy signal emerged 31 days prior and analysts assigned a buy rating.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.